⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7104332 | 0.46 | — | — | |
| Hydrochloric Acid SCHEMBL72335 | 0.43 | — | — | |
| SCHEMBL31437084 | 0.37 | TSHR (0.50) | — | |
| Hydrochloric Acid SCHEMBL28241565 | 0.35 | — | — | |
| Hydrochloric Acid SCHEMBL28357143 | 0.35 | — | — | |
| Hydrochloric Acid SCHEMBL14910951 | 0.35 | — | — | |
| Hydrochloric Acid SCHEMBL10625472 | 0.35 | — | — | |
| Water SCHEMBL21986451 | 0.35 | — | — | |
| Hydrochloric Acid SCHEMBL28477348 | 0.35 | — | — | |
| Hydrochloric Acid SCHEMBL7847798 | 0.30 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107709658-B | Oxidation process | 卡特克塞尔科技有限公司 | 2021-04-09 | — | — | CN | claimed |
| EP-3307940-B1 | OXIDATIVE METHOD | CATEXEL TECH LIMITED (GB) | 2021-03-24 | — | — | EP | claimed |
| US-10815616-B2 | Oxidative method | CATEXEL TECHNOLOGIES LIMITED (GB) | 2020-10-27 | — | — | US | claimed |
| US-20180094384-A1 | OXIDATIVE METHOD | CATEXEL B.V. (NL) | 2018-04-05 | — | — | US | claimed |
| EP-2091926-B1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | claimed |
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | claimed |
| EP-1765789-B1 | N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2013-02-27 | — | — | EP | claimed |
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | CHIRON CORPORATION | 2013-01-17 | — | — | US | claimed |
| US-8318791-B2 | Substituted imidazole derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-11-27 | — | — | US | claimed |
| US-8129358-B2 | Substituted pyrazole and triazole compounds as KSP inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | claimed |
| US-20080200462-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG | 2008-08-21 | — | — | US | claimed |
| WO-2008063912-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | claimed |
| WO-2008054795-A2 | TRIAZOLOPYRIMIDINE DERIVATIVES AS ADP P2Y12 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-05-08 | — | — | WO | claimed |
| US-20080108635-A1 | Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-05-08 | — | — | US | claimed |
| CN-1993331-A | N- (1- (1-benzyl -4-phenyl-1h-imidazol-2-yl) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer | CHIRON CORP (US) | 2007-07-04 | — | — | CN | claimed |
| EP-1765789-A1 | N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-03-28 | — | — | EP | claimed |
| US-20060009472-A1 | Substituted imidazole derivatives | CHIRON CORPORATION | 2006-01-12 | — | — | US | claimed |
| WO-2006002236-A1 | N- (1- (1-BENZYL -4-PHENYL-1H-IMIDAZOL-2-YL) -2,2-DYMETHYLPROPYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-01-05 | — | — | WO | claimed |
| EP-1226126-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-01-05 | — | — | EP | claimed |
| CN-1498218-A | Imidazo-pyrimidine derivatives as GABA receptor ligands | Ĭ�ˡ�����-��ķ��˾ | 2004-05-19 | — | — | CN | claimed |